Tango Therapeutics holds routine annual meeting, elects two directors and ratifies auditor

Filed June 4, 2026 · Period ending June 4, 2026 · ~1 min read

Key Changes

• low

  Shareholders elected Malte Peters, M.D. and Mace Rothenberg, M.D. as Class II directors to serve until 2029, with both receiving strong majority support.

  Item 5.07 verify on EDGAR →
• low

  PricewaterhouseCoopers was ratified as independent auditor for fiscal 2026 with over 99% approval from voting shareholders.

  Item 5.07 verify on EDGAR →
• low

  Executive compensation received 98% shareholder approval in non-binding advisory vote, indicating strong support for management pay practices.

  Item 5.07 verify on EDGAR →